EU Clinical Trial 2017-004758-40

A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer  Feb 22, 2019

Main objective of the trial: Dose escalation: To establish the MTD and RP2D of tisotumab vedotin in combination in subjects with cervical cancer Dose expansion: Evaluate the antitumor activity of tisotumab vedotin in combination in subjects with cervical cancer

Parties

Sponsors
Countries
BE CZ DE DK EU GB IE IT NL TR US
Keywords
Avastin BEVACIZUMAB Carboplatin Cervix carcinoma IgG1-1015-011-1006 Keytruda PEMBROLIZUMAB Tisotumab vedotin tisotumab vedotin

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.